Wed, Jul 30, 2014, 4:27 AM EDT - U.S. Markets open in 5 hrs 3 mins

Recent

% | $
Click the to save as a favorite.

Celgene Corp. (CELG) Message Board

  • rob_cos rob_cos Dec 7, 2011 11:11 AM Flag

    PJ:"ASH expectations low, time to buck the trend" $89 target Outperform

    Piper Jaffray

    Healthcare

    Biotech - ASH preview = we will be attending the American Society of Hematology conference from December 10-13, where Celgene and Incyte will present updated Phase III data from trials of Revlimid and Jakafi, respectively. We believe expectations heading into the conference for Celgene are low, potentially allowing CELG shares to buck the trend and do well exiting the conference. We expect the focus for Celgene to be on subgroup analysis of the MM-015 trial, specifically ages 65-75, where a statistically significant improvement in progression free survival (PFS) could confirm “trends” toward an overall survival (OS) benefit, despite a crossover trial design. In addition, we expect Phase II data for pomalidomide in refractory multiple myeloma to support an accelerated filing in 1Q12. For Incyte, investor focus remains on Jakafi’s launch. We expect physicians to confirm a desire to use Jakafi, but 1Q12 sales will likely be impacted by the Medicare donut hole.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Agree with Piper

    • Setting up for a big run next week - chart looks amazingly positive for a strong long base move

    • 100% right - the expectatioins are so low - the panic is palatable - but yet CELG is still way over the 50s ortigia has predicted 20 times now inaccurately.

      Actual news will be infintely better than the expectations.

      Piper Jaffray
      CELGENE
      $89 target

      Healthcare

      Biotech - ASH preview = we will be attending the American Society of Hematology conference from December 10-13, where Celgene and Incyte will present updated Phase III data from trials of Revlimid and Jakafi, respectively. We believe expectations heading into the conference for Celgene are low, potentially allowing CELG shares to buck the trend and do well exiting the conference. We expect the focus for Celgene to be on subgroup analysis of the MM-015 trial, specifically ages 65-75, where a statistically significant improvement in progression free survival (PFS) could confirm “trends” toward an overall survival (OS) benefit, despite a crossover trial design. In addition, we expect Phase II data for pomalidomide in refractory multiple myeloma to support an accelerated filing in 1Q12. For Incyte, investor focus remains on Jakafi’s launch. We expect physicians to confirm a desire to use Jakafi, but 1Q12 sales will likely be impacted by the Medicare donut hole.

 
CELG
87.73+0.09(+0.10%)Jul 29 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.